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Abstract
Background: In addition to the established indications of tremor and dystonia, deep brain stimulation (DBS) has been utilized less commonly for several
hyperkinetic movement disorders, including medication-refractory myoclonus, ballism, chorea, and Gilles de la Tourette (GTS) and tardive syndromes. Given the
lack of adequate controlled trials, it is difficult to translate published reports into clinical use. We summarize the literature, draw conclusions regarding efficacy when
possible, and highlight concerns and areas for future study.
Methods: A Pubmed search was performed for English-language articles between January 1980 and June 2014. Studies were selected if they focused primarily on
DBS to treat the conditions of focus.
Results: We identified 49 cases of DBS for myoclonus-dystonia, 21 for Huntington’s disease, 15 for choreacanthocytosis, 129 for GTS, and 73 for tardive
syndromes. Bilateral globus pallidus interna (GPi) DBS was the most frequently utilized procedure for all conditions except GTS, in which medial thalamic DBS was
more common. While the majority of cases demonstrate some improvement, there are also reports of no improvement or even worsening of symptoms in each
condition. The few studies including functional or quality of life outcomes suggest benefit. A limited number of studies included blinded on/off testing. There have
been two double-blind controlled trials performed in GTS and a single prospective double-blind, uncontrolled trial in tardive syndromes. Patient characteristics,
surgical target, stimulation parameters, and duration of follow-up varied among studies.
Discussion: Despite these extensive limitations, the literature overall supports the efficacy of DBS in these conditions, in particular GTS and tardive syndromes.
For other conditions, the preliminary evidence from small studies is promising and encourages further study.
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Introduction
Hyperkinetic movement disorders are a heterogeneous group of
conditions, the complexity of which makes treatment challenging.
Pharmacologic treatment is often inadequate and fraught with side
effects. Past success with surgical lesioning procedures led to the study
of deep brain stimulation (DBS) as an alternative approach. This
review will focus on DBS in hyperkinetic movement disorders,
including myoclonus, ballism, chorea, tardive syndromes, and Gilles
de la Tourette’s syndrome. The majority of the literature is in the form
of case reports, case series, and small, non-blinded, uncontrolled
studies. We will review the major themes and lessons among these
reports, and focus on studies involving blinded assessments, on/off
stimulation testing, and controlled study design when available.
Despite several challenges inherent to summarizing this literature,
including wide variation in patient selection, outcome measures,
duration of follow-up, surgical targets, and stimulation parameters, we
endeavor to present the existing literature in a format that is useful for
both clinicians and researchers in this field.
Search strategy and selection criteria
A Pubmed search was performed for English-language articles
between January 1980 and June 2014. Search keywords were deep
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brain stimulation and neurostimulation, and myoclonus, ballism,
hemiballism, chorea, hemichorea, choreathetosis, neuroacanthocyto-
sis, choreacanthocytosis, tardive, tic, and Tourette. Studies were
selected if they focused primarily on DBS to treat these conditions.
Myoclonus
Myoclonus involves sudden brief jerks due to muscle contraction or
lapse in contraction and has several possible etiologies. DBS has most
often been used for the syndrome of myoclonus-dystonia (M-D), an
autosomal dominant disorder associated with mutations in the epsilon-
sarcoglycan (SGCE) gene. Action myoclonus begins in childhood or
adolescence, in association with cervical and limb dystonia. Medical
therapies such as anticholinergics and benzodiazepines are often
ineffective and poorly tolerated.
Patient selection and outcomes
The earliest reported cases of DBS for M-D targeted the
ventrointermediate nucleus of the thalamus (Vim)1 and globus pallidus
interna (GPi)2 based on experience with these targets for tremor and
dystonia, respectively. To date, there have been 49 cases reported in
22 publications (Table 1). In the largest case series to date, Gruber and
colleagues studied 10 patients, eight of whom were implanted with
both bilateral GPi and Vim DBS.3 The Unified Myoclonus Rating
Scale (UMRS) score and Burke–Fahn–Marsden Dystonia Rating Scale
(BFMDRS) disability score improved significantly in all patients by 61–
66% and 45–48%, respectively, compared with the pre-surgical
baseline. Combination GPi–Vim stimulation resulted in significantly
better UMRS scores than Vim stimulation alone; there was no
significant difference between GPi–Vim and GPi alone, or between
GPi and Vim each alone. Using a similar approach, Oropilla et al.4
reported that either target improved myoclonus and dystonia assessed
with double-blind on/off testing, but that GPi performed better than
Vim.
A meta-analysis by Rughani and Lozano5 reviewed 40 cases in 17
reports.1–4,6–18 The UMRS improved by at least 50% in 93.5% of
cases, and the BFMDRS improved by at least 50% in 72% of cases.
The greater improvement in myoclonus than in dystonia was
statistically significant (p,0.001). Although myoclonus improved
similarly with either surgical target, there was a statistically significant
difference for dystonia favoring GPi over Vim (60.2% vs. 33.3%
improvement, p50.03). In addition, a small number of patients
experienced unchanged (n53) or worsened dystonia (n51). These
results suggest that myoclonus improves more consistently and to a
greater degree than dystonia. Factors predictive of positive response
included younger age and shorter duration of symptoms.5
Since publication of this meta-analysis, there have been seven
additional reports of GPi DBS for M-D. Four of these cases were SCGE
positive with an excellent response for both myoclonus and
dystonia.19,20 Three cases of SCGE-negative patients had less robust
but still positive outcomes;21,22 however, there is insufficient literature
comparing SCGE-positive and negative cases to draw conclusions
about their relative response to DBS.
Stimulation parameters and adverse effects
In Gruber et al.,3 stimulation parameters were inconsistent, with
frequency ranging from 130 to 250 Hz at the Vim, and 130–180 Hz at
the GPi, and pulse width ranging from 60 to 210 ms at each target.
Vim stimulation was associated with more adverse effects, including
dysarthria in seven patients and worsened dystonia in five patients.
Non-stimulation-related adverse effects included infections (n52), lead
breakage (n51), and intracerebral hemorrhage (n51). In the second
largest case series (n55), no adverse events occurred.6
Summary
In summary, all published reports of DBS for M-D, the vast
majority of which utilized bilateral GPi DBS, describe at least some
benefit. GPi stimulation may be more advantageous for dystonia, with
similar effects on myoclonus and fewer stimulation-related adverse
effects than Vim. There have not been any controlled studies to date.
Blinded on/off stimulation testing periods have been short in duration,
allowing potential residual benefit, and stimulation parameters have
not been specifically compared. All of these limitations should be
addressed in future studies.
Reports of DBS in secondary myoclonus include two cases of
anoxia-related action myoclonus that have improved, one with
unilateral GPi DBS and one with bilateral thalamic DBS.23,24
Ballism
Ballism is an involuntary large amplitude movement of the
proximal limb, classically associated with subthalamic nucleus
(STN) lesions, but also arising due to other structural or metabolic
insults and often coexisting with hemichorea (hemiballism–hemi-
chorea or HBHC). In one case of HBHC secondary to hyperglyce-
mia, thalamic DBS reduced chorea and ballism. Ballism was
exacerbated off stimulation 9 months post-operatively, which argues
against spontaneous remission.25 In one case of hemiballism and
hemidystonia secondary to STN hemorrhage, GPi DBS alleviated
both dystonia and ballism.26 In a revealing case of HBHC following
craniopharyngioma resection, both Vim and GPi intraoperative test
stimulation suppressed ballism.27 This very limited literature suggests
that either thalamic or GPi DBS may improve ballism. Because
hemiballism due to a transient insult may improve with time, future
reports would be strengthened by blinded on/off testing over longer
follow-up periods.
Chorea
Chorea consists of involuntary, irregular movements that flow
randomly from one body part to another. It is seen in a variety of
conditions, including Huntington’s disease (HD), chorea-acanthocy-
tosis (ChAc), cerebral palsy (CP), and secondary and idiopathic senile
forms.
Huntington’s disease
HD is a neurodegenerative disease primarily characterized by
chorea, cognitive decline, and psychiatric features, but also involving
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other movement disorders including dystonia, parkinsonism, and
ataxia. Through effects on swallowing, gait, and balance, chorea can
be associated with significant morbidity. Twenty-one cases treated with
DBS have been reported in 12 studies targeting GPi (Table 2).28–39 A
single case targeted globus pallidus externa (GPe), but did not report
clinical outcome.40 Quadruple GPi and STN DBS was utilized in a
single case.38
Patient selection and outcomes. All patients had confirmed genetic
HD, but other patient characteristics varied among the studies
(Table 2). Most reports required chorea to be refractory to
medications and causing functional impairment. Patients with
unstable psychiatric disease and severe cognitive impairment were
excluded, though no clear cut-offs on neuropsychologic testing were
reported.
All studies described improvement in the Unified Huntington’s
Disease Rating Scale (UHDRS) total score (mean 24.4%) and chorea
subscore (mean 58.2%). The largest study was a prospective open-label
trial by Gonzalez et al.39 In this study, surgical targeting was
performed with interventional magnetic resonance imaging without
microelectrode recordings. Improvement in the UHDRS chorea
subscore was sustained over the follow-up period, though the total
UHDRS score was not significantly improved after 6 months,
suggesting that other motor features of HD, such as dystonia and
parkinsonism, may not respond as well as chorea over time. This study
was limited by its open-label design, unblinded clinical examinations,
and lack of quality of life or global impression measures. In two studies,
DBS improved chorea-related complications, including dysphagia,
involuntary vocalizations, and marked weight loss, with profound
impact on quality of life.34,39














Studies with double-blind on/off stimulation testing
Unilateral
GPi and Vim
1 0 24 nra 59.5 Oropilla et al.4
Studies with rater-blinded on/off stimulation testing
GPi 4 4 50.3 (12–108) 41.8 (241.7–77.8)b 67.1 (59–80.4) Gruber et al.3
Vim 2 2 64.5 (1–128) 75.5 (70–81) 43.3 (31.6–55) Gruber et al.3
GPi and Vim 4 3 41.5 (15–76) 21.0 (0–45.8) 59.5 (40.7–69.8) Gruber et al.3
Studies with rater-blinded video assessments
GPi 5 5 15–18 85 (70–91) 83 (73–93) Azoulay-Zyss et al.6
Other studies
GPi 31c 11 22.5 (1–128) 71.8 (50–100) 64.9 (31.3–89) Vercueil et al.,2 Beukers et al.,7
Cif et al.,8 Contarino et al.,9
Fonckeet al.,10 Jog and Kumar,11
Kuncel et al.,12 Kurtis et al.,13
Magarinos-Ascone et al.,14
Liu et al.,15 Papuc et al.,16 Wang
et al.,17 Yianni et al.,18 Ghosh
et al.,19 Uruha et al.,20
Sidiropoulos et al.,21 Kim et al.,22
Vim 2 1 16.5 (9–24) nr 66.5 (53–80) Trottenberg et al.,1 Jog and
Kumar11
Abbreviations: BFMDRS, Burke–Fahn–Marsden Dystonia Rating Scale; GPi, Globus Pallidus Interna; nr, Not Reported; SGCE+, Sarcoglycan-Epilson Mutation-Positive;
UMRS, Unified Myoclonus Rating Scale; Vim, Ventrointermediate Nucleus of the Thalamus.
a81% improvement in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS).
bNegative value indicates worsening.
cIn 17 reports.
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1 43 8 8 R: C+22 3.5 V/120 ms/40 Hz 31.4 44.0 Moro et al.28
L: C+22 5 V/90 ms/40 Hz
1 41 13 12 Bilateral: R:
C+02
2.8 V/120 ms/180 Hz 37.5a 50a Hebb et al.29
1 60 10 48 Bilateral: 122+ 1.9 V/450 ms/130 Hz 5.4b 21.4b Biolsi et al.30
1 72 17 12 Bilateral: C+12 2.0 V/90 ms/40 Hz nr 82.4 Fasano et al.31
2 57 10 24 R: 021+ 3.6 V/180 ms/160 Hz 45.3 62.5 Kang et al.32
L: 0+12 3.6 V/180 ms/130 Hz
50 5 24 R: 120+ 3.6 V/210 ms/130 Hz 11.1 50 Kang et al.32
L: 1+22 3.6 V/210 ms/130 Hz
1 30 9 24 Bilateral:
C+0212
2.0 V/60 ms/130 Hz 15.2 75 Spielberger et al.33
1 30 10 12 Bilateral C+02 3.6 V/60/130 30.2 nr Garcia-Ruiz et al.34
1 40 3 12 Bilateral:
C+0212
1.5 V/90 ms/130 Hz 24 nr Huys et al.35
1.5 V/90 ms/130 Hz
1 31 15 48 nr 2.0 V/210 ms/80 hz 17.8 100 Cislaghi et al.36
2 34 7 12 Bilateral: C+12 2.0–3.2 V/150 ms/60–
80 hz
11.8 73.7 Velez-Lago et al.37
25 6 12 Many tried Many tried 9.8 n/ac Velez-Lago et al.37
1 41 9 48 GPi R:C+22 0.5 V/160 Hz 38.2 50 Gruber et al.38,d
L:C+22 1.0 V/160 Hz
STN R: 322+ 5.0 V/40 Hz

































































In order to distinguish ongoing benefit of DBS from spontaneous
remission of chorea, unblinded on/off stimulation testing was
performed in seven studies, at anywhere from 12 months to 4 years.
In the majority, chorea was exacerbated within minutes off stimula-
tion.29,30 In the Gonzalez study, the chorea subscore was significantly
different between on and off conditions at 18 months and last follow-
up.39 However, in other reports, chorea was unchanged with
stimulation off, from 1 to 4 years post-operatively.31,32,36
Despite overall persistent benefit for chorea, bradykinesia, rigidity,
and gait impairment may not respond or may even worsen after DBS.
It remains unclear to what extent this is due to stimulation-induced
side effects, as some cases improve with a decrease or discontinuation
of stimulation37 whereas others do not.29,31 Disease progression likely
accounts for clinical worsening post-operatively in some cases. Despite
persistent improvement of chorea, several cases have demonstrated
progressive bradykinesia, speech impairment, gait impairment, and
cognitive decline that may limit the global impression of benefit of
DBS.31,33,39 Conversely, bradykinesia and rigidity improved in the on
stimulation state for up to 2 years of follow-up in one report.32 One
report of GPi DBS for the parkinsonism-dominant Westphal variant of
HD showed limited benefit.36 There are mixed results in dystonia-
predominant cases.37
Stimulation parameters and adverse effects. Various stimulation
strategies were employed in an effort to limit extrapyramidal side
effects. Low-frequency vs. high-frequency stimulation demonstrated
conflicting results for bradykinesia, rigidity, and gait.28,29,31,32,37,39 In
the Gonzalez study, reduction in pulse width improved bradykinesia.39
In a single case of quadripolar GPi and STN DBS, both improved
chorea equivalently, but STN improved bradykinesia and oculomotor
function more than GPi.38 Other adverse effects were infrequent in
published cases. In Gonzalez et al.,39 one patient had a hardware
complication and one required lead repositioning.
Neuroacanthocytosis
The neuroacanthocytosis syndromes are genetic conditions char-
acterized by prominent chorea and neuropsychiatric symptoms, with
red blood cell acanthocytosis. ChAc, an autosomal recessive
neuroacanthocytosis associated with VSP13A mutations in the chorein
gene, classically causes oromandibular chorea with lip and tongue
biting, tongue protrusion or feeding dystonia, and paroxysmal head/
neck and trunk movements. Though there is a single case report about
the ventral oral part of motor thalamus (Vop) DBS,41 the remainder of
the reported cases have selected the GPi target.
Patient selection and outcomes. All cases of GPi DBS for ChAc
reported to date are summarized in a worldwide retrospective cross-
sectional study by Miquel and colleagues.42 Fifteen cases were
identified, 12 of which had been previously described in the literature.
Molecular (chorein western blot) or genetic confirmation of diagnosis
was obtained in 13 out of 15 cases. The mean age at surgery was 38.7
(SD 7.3) years, with mean disease duration of 9.6 (SD 7.2) years, and
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included refractory and disabling hyperkinetic movements (chorea,
dystonia, trunk spasms, head drops) in 11 cases, and self-mutilating
behavior in six cases. All patients with UHDRS motor scores available
(13/15) significantly improved compared with baseline in the early
post-operative period (1–5 months, mean improvement 54.3%). At the
last recorded visit (6 months or longer) mean improvement was
somewhat lower at 44.1%, but 8 out of 13 (61.5%) still had a clinically
meaningful benefit of at least 20% compared with baseline. UHDRS
independence score (IS) and functional capacity score (FCS) were
significantly improved at the early visit, but only the FCS score was
significantly improved at last follow-up, suggesting that either waning
benefit from DBS or development of non-DBS-responsive symptoms
over time may limit independent function. Chorea and dystonia were
the most improved symptoms, along with trunk spasms and head
drops. Injurious orofacial movements improved in all except one
patient, and feeding status improved in six out of nine patients for
whom this information was available. Both gait and swallowing
outcomes varied greatly, improving if secondary to chorea or dystonia,
but failing to improve or even worsening if secondary to parkinsonism.
Dysarthria was refractory to DBS, and one patient experienced severe
worsening of speech related to stimulation. The severity of the baseline
UHDRS motor score, but not age or disease duration, was significantly
associated with the degree of improvement on the UHDRS motor
score.
McLeod syndrome is an X-linked neuroacanthocytosis syndrome.
In a single case, GPi DBS improved chorea and dystonia, but
hypotonia continued to limit independent ambulation.43
Stimulation parameters and adverse effects. As with DBS for HD,
ChAc cases demonstrate the complexity of programming when several
movement phenomenologies are present. The majority of the ChAc
patients (9/15) received high-frequency stimulation (130–185 Hz)
throughout the duration of follow-up. Four patients experienced
worsening of chorea with high-frequency stimulation43,44 and two
patients experienced worsened dystonia.44 In two cases with blinded
on/off testing, chorea improved at 40 Hz, but at 130 Hz chorea and
dysarthria worsened and drooling developed, and 10 Hz stimulation
had no effect.43 One patient had worsened truncal spasms with low-
frequency stimulation.45 In two patients severe truncal hypotonia was
non-responsive to DBS.43,46 Optimal stimulation settings thus appear
to be highly individualized on the basis of both the presence and the
relative contribution of various symptoms to global function. One
ChAc patient notably developed ‘‘Twiddler syndrome’’ (manual
twisting of device components leading to malfunction).42 There are
no reports of exacerbation of seizures.
Secondary and other chorea syndromes
There are case reports of DBS for secondary chorea. Unilateral GPi
DBS improved hemichorea secondary to STN developmental venous
anomaly with microhemorrhage.47 A case of hemichorea secondary to
thalamic hemorrhage responded to Vim DBS.48 As mentioned
previously, HBHC improved with DBS in two reports.25,27 A case
series reported on four patients with GPi DBS for generalized chorea
secondary to cerebral palsy. After 2 years of follow-up, two patients
had decreased injurious movements and gains in independent function
but none had statistically significant improvement by rating scales.49
Similarly, GPi DBS improved caregiver assessment of daily function in
a patient with choreoathetosis and myoclonus in the setting of cerebral
palsy.50 One patient with cerebral palsy-associated chorea was treated
with Vim DBS with patient-reported marked improvement.48 GPi
DBS improved choreoathetosis as well as stereotypic and ballistic
movements in a single case.51 A single report of DBS for senile
idiopathic chorea utilized unilateral GPi and Vop-thalamus leads and
found that thalamic stimulation produced steady benefit over 18
months of follow-up.52
Adverse outcomes in DBS for chorea
The rate of post-operative complications in these syndromes appears
to be within the range of other DBS indications. There is limited
information about the impact of DBS on cognitive and psychiatric
comorbidities in these conditions.
Summary
In summary, DBS may have a role in alleviating refractory chorea
due to various etiologies. The majority of the literature is focused on
GPi DBS in HD and ChAc, which appears to improve functional
disability in select patients. The response of parkinsonism, dystonia,
and hypotonia is more variable. These features may worsen either as a
result of disease progression or stimulation, limiting the global benefits
of DBS and complicating stimulation adjustments. Symptoms that are
not responsive to DBS, such as postural instability and cognitive
impairment, may emerge with time and cause significant disability
even if DBS continues to control chorea. Further research should
include controlled studies focused on optimal patient selection,
stimulation approaches, and assessment of benefit over long-term
follow-up. In addition, in HD, chorea can lessen over time, and this
must be distinguished from DBS-related benefits. Blinded on/off
testing would help clarify long-term effects. As DBS may be seen as a
palliative treatment, functional outcomes, quality of life, and patient
and caregiver-rated impressions of benefit will be important measures
of success.
Tics and Gilles de la Tourette’s syndrome
Gilles de la Tourette syndrome (GTS) is a childhood-onset
neuropsychiatric syndrome characterized by multiple motor and vocal
tics. Tics are sudden, repetitive, stereotyped muscle contractions
(motor tics) or sounds (vocal tics) that can involve self-injurious
behavior. Patients often suffer from concurrent obsessive-compulsive
disorder (OCD), attention-deficit hyperactivity disorder (ADHD), and
mood disorders. Pharmacologic therapies are associated with side
effects including sedation, weight gain, and drug-induced movement
disorders. Based on the success of surgical lesioning in medial thalamic
targets, the first DBS procedure for GTS was performed in 1999.53
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CM-Pf 5 RCT 3 28.2 (18–34) 44 (211.9–63.3)a 44.4 Maciunas et al.59
5 CR 6–18 23.4 (17–35) 70.5 (60–81.8) nr Pullen et al.,68 Savica et al.,69
Lee et al.70
CM-Voi-Spv 6 RCT 12 40.3 (35–48) 49 (26.1–94.7) 70 Ackermans et al.60
4 CR 8–120 36 (20–45) 66.3 (7–92.6) 65b Vandewalle et al.,53
Visser-Vandewalle et al.,65
Ackermans et al.,66 Duits
et al.,67 Ackermans et al.71
CM-Pf-Voi 31c CS 3–72 32 (17–57) 47 (5–88) 17.3 (227.5–90)a Servello et al.61
6 CR 12–24 26.4 (19–48) 50.6 (29.1–66) 33.0 (253–100)a Bajwa et al.,72 Kaido et al.,73
Idris et al.,74 Rzesnitzek
et al.75
VA/VL 8 CS 12 33.3 (19–56) 58 50 Huys et al.58
Vo 7 CS 6–24 36.6 (24–52) 33 (9.5–48.6) 3 (247.1–23.8)a Marceglia et al.63
CM 5 CS 4–6 34.4 (28–39) 25 nr Maling et al.64
Thalamusd 4 CS 6–95 28.5 (16–44) 44.8 (7–85) 13.8 (235–100)a Motlagh et al.56




3 CR 12 23.7 (22–26) 62.0 (35.9–82.6) nr Kuhn et al.77
Globus pallidus interna
Am or Pvl GPi 5 CS 3–24 37.8 (21–60) 29 (10.8–62.8) 26 Martinez-Fernandez R
et al.79
Pvl GPi 4 CS 5–48 33.8 (25–44) 40.75 (26–88)a nr Dehning et al.,80 Dehning
et al.81
6 CR 6–51 27.8 (16–44) 48.8 (20–84) 43 (17–69) Motlagh et al.,56 Ackermans
et al.,71 Diederich et al.,82
Gallagher et al.,83 Shahed


































































Am GPi 17 CS 4–30 29.1 (17–51) 54.3 (0–85.2) 61.9 (26.0–100) Cannon et al.,85 Sachdev
et al.86
2 CR 12–24 17 (15–19) 58.2 (55.4–61) nr Huasen et al.,57 Massano
et al.78
Ventral GPie 2 CR 12 31.5 (22–41) 55.8 (53–59) nr Dong et al.87
GPi 1 CR 6 21 47 nr Patel and Jimenez-Shahed90
Anterior limb internal capsule or nucleus accumbens
NA 4 CR 7–36 32 (26–38) 61.1 (41–80) 64.2 (52–84.6) Kuhn et al.,92 Zabek et al.,93
Sachdev et al.,95 Neuner
et al.96
ALIC/NA 3 CR 10–30 35.7 (27–47) 25.4 (217–68.1)a 27.2 (0–54.3) Flaherty et al.,94 Burdick
et al.,97 Servello et al.98
Combination targets
CM-Pf and Am GPi 4 CS 20–60 33 (30–36) 62.3 (43–76) nr Houeto et al.,102 Welter
et al.103
CM-Pf and Pvl GPi 1 CR 12 45 nr nr Ackermans et al.71
Am or Pvl GPi and
midline thalamus
2 CR 37–107 33.5 (19–48) 0, 72 n/a, 72.4 Motlagh et al.56
ALIC then CM-Pf-
Vo/Voi
3f CR 3–44 31.7 (24–40) 45.3 (31.6–60) 14.2(221.7–34.2)a Servello et al.,61 Servello
et al.,98 Shields et al.99
Pvl GPi then ALIC/
NA
1 CR nr 42 49.3 38.2 Servello et al.61
Abbreviations: ALIC, Anterior Limb of Internal Capsule; Am, Anteromedial; CM, Centromedian; CR, Case Report with ,3 Patients; CS, Case Series with .3 Patients; DM, Dorsomedial
Nucleus; GPi, Globus Pallidus Interna; LM, Lamella Medialis; NA, Nucleus Accumbens; n/a, Not Applicable; nr, Not Reported; Pf, Parafascicular Nucleus; pvl, Posteroventrolateral; RCT,
Randomized Controlled Trial; Spv, Spinal Trigeminal Nucleus; VA, Ventral Anterior Thalamic Nucleus; VL, Ventral Lateral Thalamic Nucleus; Vo, Ventral Oral; Voi, Ventral Oral Internal;
YBOCS, Yale–Brown Obsessive Compulsive Scale; YGTSS, Yale Global Tic Severity Scale.
aNegative value indicates worsening.
bReported in single case (Duits et al.67).
cOne case was unilateral, 18 were followed for 60–72 months, ranges for outcomes reflect these 18 patients reported in Porta et al.62
dTarget was 5 mm lateral, 4 mm posterior, 0 mm beneath anterior commissure-posterior commissure (AC-PC).
eUnilateral.



























































% Change in AIMS
Mean (range)




10 6 – – 56 (33–78) 61 (44–75) Damier et al.126
Case series using rater-blinded video assessments
5 24–96 M/D 71 (23–100)a/48 (0–94)a – 77 (0–73)a Chang et al.129
1 5.9 – – 90 – Pretto et al.130,b
Case reports using double-blind on/off testing
1 6 T 91 77 – Kefalopoulou et al.121
1 5 – – 63 – Schrader et al.108
1 6 T 73 54 – Trottenberg et al.106
Case series of .3 patients
9 18–80 M/D 83 (63.6–100)/68 (25–
100)
79 (33.3–100) – Gruber et al.119
6 3–39 M/D 86 (58–100)/80 (67–
100)
– – Sako et al.118
5 6 M/D 87 (75–98)/96 (80–100) 78 – Trottenberg et al.112
5 3–84 M/D 47 (0–92)/55 (0–92) – – Egidi et al.115,b
4 8–35 T 59.8 (6–100) – – Starr et al.113,b
Case reports of 1–3 patients (compiled from 16 reports)c
25f 3–120 (mean
22.4)
M 49.4(22.4–97) 60.3 (42–77)d – Eltahawy et al.,107 Krause et al.,109
Franzini et al.,110 Halbig et al.,111
Cohen et al.,114 Kosel et al.,116
Magarinos-Ascone et al.,117 Katsakiori
et al.,120,121 Capelle et al.,122 Kim et
al.,123 Spindler et al.,124 Trinh et al.,125
Boulogne et al.,128 Zhang et al.132,e
D 48.7 (0–100)
T 69.0 (31–93)
Abbreviations: –, not reported; AIMS, Abnormal Involuntary Movements Scale; BFMDRS, Burke-Fahn–Marsden Dystonia Rating Scale; D, Disability Subscore; ESRS, Extrapyramidal Symptoms Rating
Scale; GPi, Globus Pallidus Interna; M, Motor Subscore; T, Total.
aApproximate, individual scores not presented.
bReports of tardive dystonia patients within a larger cohort of primary and/or secondary dystonia patients.
cOutcomes available were averaged, as not all cases reported every outcome.
dTotal number of patients in 16 reports.
eSurgical target was subthalamic nucleus rather than GPi.




















































There are 129 cases reported in the literature, 115 of which were
recently reviewed.54
Patient selection and outcomes
Patient selection criteria vary among the reported cases, and though
guidelines have been proposed, components of these criteria are
debated.55 Proposed criteria state that tics should be ‘‘severe;’’
however, severity may be poorly captured by rating scales, as tics
tend to fluctuate, are suppressible, and may be exacerbated by
environmental factors. Another proposed criterion is that tics are
treatment refractory, defined as unsatisfactory response or unaccep-
table side effects to three different medications, including a typical and
atypical neuroleptic, as well as behavioral therapy.55 Some authors
advocate a minimum age of 25 since symptoms typically improve in
early adulthood,55 while others suggest DBS in younger patients may
be associated with better tic control and functional outcomes.56 Tics
that could result in permanent injury may justify DBS at an earlier
age.57 A prospective open-label trial found that lower baseline
compulsivity and anxiety scores, but not age at surgery, were
significantly associated with tic improvement after DBS.58 Future
studies should determine patient characteristics predictive of outcomes
and standardize patient selection criteria.
A variety of surgical targets have been utilized with at least partial
success in GTS. The pathophysiology of GTS is thought to involve
aberrant cortico-striato-thalamo-cortical circuitry, and modulation of
this circuitry by DBS at several different targets in the pathway appears
to have benefits.
Thalamus. The most frequently utilized surgical target for GTS is the
medial thalamus, including the centromedian (CM), parafascicular (Pf)
and ventro-oralis internus (Voi) nuclei. There are 85 individual cases
reported with overall clinical success (Table 3).56,58–77 Servello and
colleagues61 published the outcomes of 30 bilateral CM-Pf-Voi DBS
cases. There was a statistically significant decrease in the Yale Global
Tic Severity Scale (YGTSS) from 75.5 to 40.0 at last follow-up. Since
isolated improvement in tics may not ultimately yield functional
improvement, it is noteworthy that there was a significant improve-
ment in the Yale–Brown Obsessive Compulsive Scale (YBOCS),
depression, anxiety, and patient-rated impact of GTS on a daily life
visual-analog scale. These improvements were maintained for at least 2
years in the 19 patients who reached this endpoint. Quality of life and
global assessment of function also improved in a prospective open-label
trial of bilateral ventral anterior thalamic nucleus (VA)/ventral lateral
thalamic nucleus (VL) thalamus DBS in eight GTS patients.58 Possibly
related to the selection of a motor thalamic target, there was no
significant change in obsessive-compulsive symptoms.
There are two randomized, double-blind studies of thalamic DBS
for refractory GTS. Maciunas and colleagues59 performed 7-day
periods of four different conditions (off, right, left, and bilateral
stimulation) followed by 3 months of unblinded bilateral stimulation.
While there was a significant difference in the Modified Rush
Videotaped Rating Scale (mRVRS) among the different conditions,
there was no significant difference in the YGTSS. After 3 months of
open-label stimulation, these rating scales improved moderately, by
40% and 44% respectively, and two of five patients had suboptimal
clinical response for unclear reasons. In a crossover study by
Ackermans et al.,60 six participants were randomized to 3 months
on or off stimulation, followed by crossover, then by 6 months of
unblinded stimulation. There was significant improvement in YGTSS
(37%) on stimulation compared with off stimulation, with vocal tics
improving more than motor tics. The degree of improvement was
greater with unblinded stimulation (49%). These studies highlight the
importance of the placebo effect in this condition. The Ackermans trial
reported stimulation-related side effects in all patients, most commonly
lack of energy and subjective visual disturbance.
Globus pallidus interna. GPi is the second most commonly utilized
target in GTS, and approaches have targeted anteromedial or
posteroventral GPi in a total of 37 cases (Table 3).56,57,71,78–90 The
largest case series (n511) targeted anteromedial GPi, and reported
significant reduction in motor and vocal tics in all except one patient,
as well as improvement in obsessive-compulsive symptoms, quality of
life, and global function.85 Dehning and colleagues88 reported six
patients who underwent posteroventral GPi DBS, four of whom had a
dramatic reduction in YGTSS (97%) and significant improvement in
quality of life/global function. However, reports of patients who
received little to no benefit raise concern and highlight the need for
further study of this target.85,88,89
Anterior limb of the internal capsule and nucleus accumbens. The
third most commonly utilized target for GTS is the anterior limb of the
internal capsule-nucleus accumbens (ALIC-NA), which has been
shown to improve OCD,91 and has thus been targeted in GTS patients
with severe OCD. In seven published cases, obsessive-compulsive
symptoms responded well, but tic response was highly variable
(Table 3).92–97 A single case had worsening of tics and no change in
OCD.97 Another strategy reported is ‘‘rescue’’ ALIC-NA DBS if
thalamic or pallidal DBS successfully controls tics but not obsessive-
compulsive symptoms.98,99
There is a single report of GPe DBS with significant improvements
in tic severity, anxiety and depression at 2 years.100 STN DBS was
performed in a patient with concurrent diagnoses of GTS and
Parkinson’s disease with near complete resolution of tics at 1 year.101
Comparisons between targets. Comparison of targets between studies
is limited by variation in anatomic coordinates utilized, small sample
sizes, variable length of follow-up, and heterogeneous patient and
clinical characteristics. Both Houreto et al.102 and Welter et al.103
attempted to overcome these limitations by comparing targets within
individual patients in a blinded fashion (Table 3). In Houreto et al.,102
CM-Pf thalamus and anteromedial GPi stimulation alone and in
combination yielded similar improvement in tic severity (65–70%) and
self-injurious behavior, while thalamic stimulation was more beneficial
for mood and impulsivity. In Welter et al.,103 GPi stimulation
outperformed thalamic or combined stimulation. In both of these
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studies, sham stimulation resulted in worsening of tics, reducing the
likelihood of placebo effect.
Adverse outcomes
While psychiatric symptoms are stable or improved in most cases,
there are reports of refractory or worsening psychiatric symptoms after
both thalamic58 and ALIC/NA DBS.96,97,104 In addition, Servello et
al.61 found a significantly increased incidence of post-operative
infection of 18% in GTS compared with 3.7% in other disorders.
Possible explanations include compulsion toward touching the surgical
wound leading to infection, or even altered immune function in
GTS.54
Summary
In summary, both medial thalamic and GPi DBS may be efficacious
in GTS. ALIC-NA DBS appears to improve OCD but has not
demonstrated consistent efficacy for tics. In light of suboptimal results
in some cases, further studies are necessary to elucidate how patient
characteristics, surgical procedure, and stimulation parameters impact
outcomes. While GPi DBS may seem more successful, an adequately
powered study comparing effects on motor and vocal tics, self-injurious
behaviors, psychiatric and functional outcomes, and tolerability is
required. Future studies must also control for placebo effect,
distinguish the effects of DBS from fluctuation of tics, and include
intention-to-treat analyses to avoid excluding non-responders lost to
follow up.
Finally, new advances in DBS technology may allow individualized
therapy, such as scheduled stimulation personalized to the character-
istics of tics, or even responsive to electrophysiologic abnormalities in
individual patients.105
Tardive syndromes
Patient selection and outcomes
Tardive syndromes are a heterogeneous group of movement
disorders resulting from use of dopamine receptor blocking agents.
Tardive dyskinesia (TD) can involve both choreiform and dystonic
movements, while tardive dystonia can also occur in isolation. The first
report using DBS for TD by Trottenberg et al.106 reported
improvement with posteroventrolateral GPi but not Vim stimulation.
To date, there have been 73 cases of GPi DBS for TD (including
tardive dystonia) reported in 26 studies (Table 4).18,107–130 All except
two recent cases124,125 have been reviewed previously.124 Overall,
these reports support that GPi DBS improves refractory TD. The
mean improvements in BFMDRS motor and disability subscores were
71% and 65% in Spindler et al.,124 and 80.9% and 74% in Mentzel et
al.127 A single prospective trial demonstrated statistically significant
improvement with double-blind on/off testing.126 Among the studies,
dyskinesia and dystonia responded similarly, with no consistent
relationship between anatomic distribution of movements and
response. Phasic dystonic movements responded better than fixed
postures.110,118,120 Mentzel et al.127 did not find any covariates that
significantly correlated with response. There are also reports of
unsatisfactory response for unclear reasons.110 Responders maintained
benefits over the duration of follow-up, which was at least 2 years in
more than 20 patients, and was as long as 10 years in one patient.128
The clinical heterogeneity of these syndromes, often involving mixed
movement disorders of dystonia and choreoathetosis, complicates
measurement of motor outcomes. Compared with other etiologies of
secondary dystonia, Saleh et al.131 found that TD had a better
response, with BFMDRS improvement of 73% for TD (n533) and
35% for other etiologies (n584).
There is a single report of STN DBS for TD, with excellent
responses in two patients.132
Stimulation parameters
Stimulation parameters vary widely among the reports, possibly due
to variability in precise lead locations and/or heterogeneous clinical
manifestations. Frequency ranges from 40 to 185 Hz, with most
studies using 130–160 Hz. Nine studies use higher pulse widths
(.200 ms) as have classically been utilized in primary dystonia, while
nine studies used lower pulse widths ranging from 60 to 90 ms. One
possible stimulation-related side effect of GPi DBS is extrapyramidal
gait disorder with parkinsonism or freezing of gait. Schrader et al.133
reported that over their entire dystonia population treated with DBS,
8.5% developed a new gait disorder that was likely related to
stimulation, including two patients with TD.
Adverse outcomes
The surgical complication rate was similar to that in other GPi DBS
indications. While not all studies followed psychiatric rating scales
post-operatively, overall there appear to be very few cases of worsening
or new psychiatric comorbidities. There was a significant improvement
in mood in some reports.122 There is a single report of worsened
depression in three of 10 patients126 and a single report of psychosis
relapse.112
Other uses of DBS in hyperkinetic movement disorders
Paroxysmal non-kinesigenic dyskinesia/dystonia
Paroxysmal non-kinesigenic dyskinesia/dystonia (PNKD) is char-
acterized by episodes of choreiform, dystonic, or ballistic movements.
It may be genetic due to MR1 mutations, or may be secondary. Three
reported cases improved with DBS; none had MR1 mutations and two
were associated with peripheral injury. Two cases utilized GPi DBS,
and one utilized Vim DBS followed by additional GPi DBS.134,135
Lesch–Nyhan disease
Lesch–Nyhan disease is an X-linked recessive neurobehavioral
disorder, characterized by dystonia and self-injurious behavior. A
single case report of anteromedial and posteroventral GPi DBS
demonstrated that posteroventral GPi stimulation improved hyperki-
netic movements.136 In both this case and a prior report,137 GPi DBS
improved self-injurious behavior.
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Other secondary dystonia
DBS has been utilized for secondary dystonia due to a variety of
etiologies, including neurodegeneration with brain iron accumulation
(NBIA), X-linked parkinsonism-dystonia (Lubag syndrome), vascular,
encephalitic, hypoxic–ischemic, and post-traumatic etiologies. It is
beyond the scope of this review to discuss specific indications, and
these have been recently reviewed.131 Over 100 cases of DBS for
secondary dystonia have been reported, the majority targeting GPi.
Outcomes are variable, but broadly fall within the 20–40%
improvement range on BFMDRS. In general, outcomes appear to
be poorer in the presence of tonic dystonia, pyramidal deficits, or
structural lesions or atrophy in the basal ganglia.131
One specific secondary dystonia that has been a notable focus of
DBS research is cerebral palsy. There have been two prospective open
label studies demonstrating significant improvement on motor and
disability scores.138,139 Variability of outcomes, with some patients
receiving minimal or no improvement, may be related to clinical
heterogeneity. In addition, lead location appeared to be variable in
cerebral palsy compared with other disorders, potentially related to
structural abnormalities.
Placebo effect in DBS studies
The placebo effect complicates the assessment of DBS efficacy in the
conditions discussed. There are frequently neuropsychiatric features,
and motor symptoms may vary depending on psychological factors. In
Parkinson’s disease, the placebo effect may account for up to 39% of
the benefit of active DBS in crossover trials.140 The magnitude of the
placebo effect in hyperkinetic movement disorders is unknown. In
studies that included a double-blind clinical assessment or randomized
crossover design, stimulation was activated prior to the blinded study
period, resulting in possible unblinding of the patients and/or
clinicians. Despite these limitations, patients improved consistently
and significantly on stimulation compared with blinded off stimulation.
This is highly suggestive of efficacy beyond a placebo effect. However,
open-label extension periods resulted in further improvement. It is not
clear if this is entirely related to unblinding or due to increased benefit
with greater duration of stimulation. The sample size was too small to
analyze differences between patients randomized to active vs. inactive
stimulation first, but this would help elucidate the role of expectation in
those patients receiving inactive stimulation first. Future studies should
strive to determine the role of placebo effect in DBS for these relatively
rare indications.
Conclusion
Uncommon uses of DBS in hyperkinetic movement disorders for
which the current body of literature supports efficacy include M-D,
HD, ChAc, GTS and TD. The most common surgical target is GPi,
except for GTS in which thalamic targets are most commonly utilized.
DBS is a promising therapy for these debilitating conditions; however,
there are several limitations and concerns. For instance, there is a need
for standardized patient selection criteria and determination of
characteristics predictive of outcomes in these very heterogeneous
conditions. Double blind, controlled studies with sufficient duration of
follow-up are necessary to discriminate the effects of DBS from the
placebo effect and natural disease course. There is a great need for
comparison between surgical targets in larger prospective controlled
studies, which may also provide guidance regarding the appropriate
target selection for specific patient characteristics. Greater attention
should be paid to functional outcomes. There are also common
challenges in selecting stimulation parameters, with potential worsen-
ing of certain components of these multifaceted movement disorders.
In summary, while further studies are necessary, DBS appears to be a
beneficial therapeutic option for several hyperkinetic movement
disorders, and provides an encouraging basis for future study.
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